Targeting IL-23 a Hit in Psoriatic Arthritis
Multiple disease domains showed significant improvement
medpagetoday.com
Guselkumab Improves Psoriatic Arthritis in Phase 2a Study
Guselkumab significantly improved joint symptoms, physical function, psoriasis, enthesitis, dactylitis and…
rheumatologynetwork.com
Efficacy and Safety Results of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Background/Purpose: To evaluate the efficacy, safety,…
acrabstracts.org
Selective IL-23 Inhibitor Shines in Mid-Stage PsA Trial
Risankizumab broadly effective against joint and skin symptoms
medpagetoday.com
Risankizumab may improve joint and skin symptoms in PsA patients
Results of a dose-ranging phase II trial support further…
medwirenews.com
Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis
Background/Purpose: Interleukin-23(IL-23), a key…
acrabstracts.org